Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Subclinical Psoriatic Arthritis (DANPAPP)
NCT04515732Phase 4Unknown
- Start
- Dec 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of apremilast in psoriatic arthritis (PsA). Status: unknown.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04515732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515732.